Viracta TherapeuticsVIRX
About: Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
Employees: 40
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 40 [Q1] → 40 (+0) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
1.24% less ownership
Funds ownership: 24.22% [Q1] → 22.98% (-1.24%) [Q2]
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
49% less capital invested
Capital invested by funds: $9.7M [Q1] → $4.91M (-$4.8M) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Leerink Partners Andrew Berens 67% 1-year accuracy 2 / 3 met price target | 1,233%upside $3 | Market Perform Downgraded | 16 Aug 2024 |
RBC Capital Gregory Renza 40% 1-year accuracy 31 / 77 met price target | 1,678%upside $4 | Outperform Maintained | 15 Aug 2024 |